MedTrace Logo

Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury

NCT02444455 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-05-14

No results posted yet for this study

Summary

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.

Conditions

  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome

Interventions

BIOLOGICAL

UCMSC group

Human umbilical cord MSCs are transplanted by intravenous infusion(5×10\^5/kg) once a day,a total of three times.

Sponsors & Collaborators

  • Ivy Institute of Stem Cells Co. Ltd

    collaborator INDUSTRY

  • Affiliated Hospital to Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • Bing Liu, M.D. · 307-IVY Translational Medicine Center

  • Changqing Bai, M.D. · Department of Respiration, Affiliated Hospital to Academy of Military Medical Sciences

  • Huiying Liu, M.D. · Department of Respiration, Affiliated Hospital to Academy of Military Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2017-03-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02444455 on ClinicalTrials.gov